Research programme: anti-BAG3 antibodies - Intrepida Bio
Latest Information Update: 28 Nov 2023
At a glance
- Originator Intrepida Bio
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Apoptosis regulatory protein modulators; Signal transducing adaptor protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)